This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
IDEAL-ICU was a randomized phase 3 parallel-group trial evaluating whether early initiation of renal replacement therapy reduced 90-day mortality compared with deferred initiation in ICU patients with septic shock who developed acute renal failure.
| Feature | IDEAL-ICU |
|---|---|
| NCT ID | NCT01682590 |
| Acronym | IDEAL-ICU |
| Title | I.D.E.A.L.-I.C.U. (Initiation of Dialysis EArly Versus deLayed in Intensive Care Unit) |
| Phase | 3 |
| Status | TERMINATED |
| Start date | 2012-07 |
| Primary completion date | 2016-10 |
| Lead sponsor | Centre Hospitalier Universitaire Dijon |
2. Clinical Question
Population
ICU patients with septic shock who develop acute renal failure as defined by the "Failure" stage of the RIFLE classification.
Intervention
Early initiation of renal replacement therapy within 12 hours after diagnosis of acute renal insufficiency.
Comparator
Deferred initiation of renal replacement therapy 48 to 60 hours after diagnosis.
Primary question
Whether early initiation of renal replacement therapy would reduce 90-day mortality compared with deferred initiation.
3. Trial Design
500 patients
Parallel design
Open-label
90-day endpoint
Randomized
Parallel assignment
None
Other
Early initiation arm
- Renal replacement therapy
- Initiation within 12 hours after diagnosis of acute renal insufficiency at the "failure" stage according to RIFLE criteria
Deferred initiation arm
- Renal replacement therapy
- Initiation 48 to 60 hours after diagnosis
4. Endpoints
| Endpoint | Time frame | Description |
|---|---|---|
| Progression free survival | 90 days | To investigate whether early initiation of RRT will reduce 90-day mortality compared with deferred initiation in ICU patients with septic shock who develop acute renal failure. |
5. Planned Analysis
The registry lists the primary endpoint as progression free survival with a 90-day timeframe and describes the clinical objective as comparison of early versus deferred renal replacement therapy initiation with respect to 90-day mortality.
For a time-to-event endpoint, statistical analysis would typically involve methods that account for the timing of events and censoring, such as Kaplan-Meier estimation, survival comparisons between randomized groups, and model-based estimation of relative effects when prespecified. The ClinicalTrials.gov record does not report posted statistical analyses or outcome estimates.
6. Statistical Methodology
Randomization and causal comparison
Randomization creates the framework for comparing treatment strategies because treatment assignment is determined before outcomes occur. The resulting groups are interpreted according to their randomized assignments rather than according to treatment received after randomization.
Time-to-event analysis
Time-to-event methods are designed for outcomes where both whether an event occurred and when it occurred are important. They account for participants whose follow-up ends before an event is observed through censoring methods.
Clinical endpoint interpretation
A mortality-related endpoint evaluates differences in survival experience between randomized strategies. Interpretation requires consideration of the endpoint definition, follow-up duration, and prespecified analysis plan.
7. Statistical Methods Explained
Why use randomization?
Randomization helps balance known and unknown factors between groups, allowing differences in outcomes to be attributed more directly to the assigned strategies.
Why are time frames important for survival endpoints?
A 90-day endpoint defines the observation period. Survival analyses depend on both the occurrence of events and the time window in which those events are evaluated.
What does censoring mean?
Censoring occurs when complete event information is unavailable by the end of observation. Proper survival methods incorporate these observations rather than simply excluding them.
Why does the analysis population matter?
The population used for analysis determines how the randomized comparison is interpreted. Clinical trial analyses generally distinguish randomized efficacy comparisons from other summaries.
8. Limitations
- No posted statistical analyses: the ClinicalTrials.gov record does not report formal statistical analyses or endpoint estimates.
- Registry endpoint wording: the primary endpoint is recorded as progression free survival while the description refers to reduction in 90-day mortality.
- Open-label design: masking was listed as none, which may influence aspects of clinical management or assessment.
- Terminated status: the trial status is recorded as TERMINATED.
9. Why This Trial Matters Statistically
| Concept | How it appears in IDEAL-ICU |
|---|---|
| Randomized trial design | Randomized parallel-group phase 3 comparison |
| Time-to-event analysis | 90-day outcome timeframe |
| Clinical endpoint definition | Renal replacement timing and mortality assessment |
| Analysis planning | Importance of prespecified survival methods |